Fluidic Sciences

Fluidic Sciences is a company developing and supplying instruments for biopharmaceutical research, combining two complementary technology platforms.

Its core offering covers in-solution protein interaction characterisation without immobilisation, alongside a high-throughput picodroplet platform for single-cell screening, antibody discovery and cell line development, the latter operated under the Sphere Bio brand acquired in 2025.

The company was established following the acquisition of assets from Fluidic Analytics, which entered administration in 2023.